(Total Views: 418)
Posted On: 08/15/2019 12:32:25 PM
Post# of 149726
Approved mar 2018, commercial available april 30 2018. I never expected high numbers from Ibalizumab though because 1) MDR3 approval 2) IV every 2 weeks and 3) high cost
2018 Q2 $1,186,000 or US$924,000.
2018 Q3 $4,864,000 or US$3,713,000.
2018 fiscal year $11,611,000 or US$8,887,000
2019 Q1 sales up 44% from the previous quarter
2019 Q2 sales up 13.6% from the previous quarter
Leronlimab is getting a broader market, MDR2 is 10x bigger than MDR3. I don't believe they get the full MDR2 market, it says mdr2 with limited options. But still much bigger market, and within MDR2, my guess the decision is more up to the doctor.
2018 Q2 $1,186,000 or US$924,000.
2018 Q3 $4,864,000 or US$3,713,000.
2018 fiscal year $11,611,000 or US$8,887,000
2019 Q1 sales up 44% from the previous quarter
2019 Q2 sales up 13.6% from the previous quarter
Leronlimab is getting a broader market, MDR2 is 10x bigger than MDR3. I don't believe they get the full MDR2 market, it says mdr2 with limited options. But still much bigger market, and within MDR2, my guess the decision is more up to the doctor.
(2)
(0)Scroll down for more posts ▼
